The registration regulations will only really have effected products coming to the market from next year, and I'm sure the pharmaceutical industry will come up with new ways to market questionable drugs. Seeing as one of the big problems is how cosy industry is with it's regulators, I'm not too optimistic :( As for the drugs currently on the market, my statements are largely true, and indeed only 2 months ago AstraZeneca settled a huge case about suppression of trial data.
As for trials,well structured large multi-centre RCTs are indeed strong evidence, but unless they went on forever and considered every conceivable variable and ruthlessly tracked down every possible confounding variable, they always have some scope for error or misinterpretation. Indeed, there's a saying that goes "you only really learn about a drug after it's been used in practice for a while". Your point is a little off though, as systematic reviews consider the quality and size of individual trials and weight them accordingly, and one large well constructed trial will offset numerous small poorly constructed ones (much to the chagrin of homeopaths).